tetano
Editor, Senior Moderator
Clin Chim Acta
. 2020 Jun 8;S0009-8981(20)30258-8.
doi: 10.1016/j.cca.2020.05.047. Online ahead of print.
Evaluation of the EDI Enzyme Linked Immunosorbent Assays for the Detection of SARS-CoV-2 IgM and IgG Antibodies in Human Plasma
Christian Bundschuh[SUP] 1 [/SUP], Margot Egger[SUP] 1 [/SUP], Kurt Wiesinger[SUP] 1 [/SUP], Christian Gabriel[SUP] 2 [/SUP], Martin Clodi[SUP] 3 [/SUP], Thomas Mueller[SUP] 4 [/SUP], Benjamin Dieplinger[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma.
Methods: Using EDI[SUP]TM[/SUP] Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used.
Results: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG ≤5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after >10-15 days. After 15-22 days the "true" positivity rates were 94.4% for IgM and 100% for IgG. The "false" positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients.
Conclusions: This study shows high "true" vs. low "false" positivity rates for the EDI[SUP]TM[/SUP] SARS-CoV-2 IgM and IgG ELISAs.
Keywords: COVID-19; ELISA; SARS-CoV-2; antibody testing; serological test.
. 2020 Jun 8;S0009-8981(20)30258-8.
doi: 10.1016/j.cca.2020.05.047. Online ahead of print.
Evaluation of the EDI Enzyme Linked Immunosorbent Assays for the Detection of SARS-CoV-2 IgM and IgG Antibodies in Human Plasma
Christian Bundschuh[SUP] 1 [/SUP], Margot Egger[SUP] 1 [/SUP], Kurt Wiesinger[SUP] 1 [/SUP], Christian Gabriel[SUP] 2 [/SUP], Martin Clodi[SUP] 3 [/SUP], Thomas Mueller[SUP] 4 [/SUP], Benjamin Dieplinger[SUP] 5 [/SUP]
Affiliations
- PMID: 32526218
- DOI: 10.1016/j.cca.2020.05.047
Abstract
Background: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma.
Methods: Using EDI[SUP]TM[/SUP] Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used.
Results: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG ≤5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after >10-15 days. After 15-22 days the "true" positivity rates were 94.4% for IgM and 100% for IgG. The "false" positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients.
Conclusions: This study shows high "true" vs. low "false" positivity rates for the EDI[SUP]TM[/SUP] SARS-CoV-2 IgM and IgG ELISAs.
Keywords: COVID-19; ELISA; SARS-CoV-2; antibody testing; serological test.